<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158505</url>
  </required_header>
  <id_info>
    <org_study_id>HR-BLTN-016</org_study_id>
    <nct_id>NCT04158505</nct_id>
  </id_info>
  <brief_title>Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer</brief_title>
  <official_title>Real World Study on the Efficacy and Safety of Pyrotinib in the Treatment of HER2 Positive Breast Cancer: An Observational,Multi-center,Prospective Study (Real Pretty Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Non-Interventional Study will describe and analyze the clinical use of pyrotinib in
      clinical practice in the treatment of HER2 positive breast cancer in the real world.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Progression Free Survival(PFS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological Complete Response（pCR）Rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Percentage of Participants With Pathological Complete Response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidences of adverse events and toxicities</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Incidences of adverse events and toxicities</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>non-interventional study</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional</intervention_name>
    <description>This prospective, observational study will be conducted according to each site's routine clinical practice</description>
    <arm_group_label>non-interventional study</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HER2+ breast cancer patients whose treatment decision with pyrotinib has been made by their
        physician and who meet the eligibility criteria will be invited to participate in the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years old with histologically confirmed HER2 positive breast cancer.

          2. Documented HER2 overexpression by local laboratory ,defined as immunohistochemistry
             (IHC) 3+ or fluorescence in situ hybridization (FISH) positive.

          3. Physician has determined that treatment with pyrotinib is indicated.

          4. Traceable medical record available.

        Exclusion Criteria:

          1. Patients who are unable to understand the nature of the study and are unwilling to
             sign an informed consent .

          2. Pregnant or breast feeding patients

          3. Patients participating in any interventional clinical trial that includes
             investigational or marketed products at the time of enrollment.

          4. Patients not suitable for this study under investigators' consideration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xu Binghe</last_name>
    <phone>+86-10-87788120</phone>
    <email>xubinghe@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Yiqun</last_name>
    <phone>+86-10-87788120</phone>
    <email>Liyiqun_chcams@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Binghe, M.D.</last_name>
      <phone>86-10-88788826</phone>
      <email>xubinghe@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>pyrotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

